VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
AMGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
AMGNAmgen Inc.
$406.09$219.2B
Overview & Tools
OverviewChart Terminal ↗AnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksAMGNAnalysis
AMGN logo

Amgen Inc. (AMGN) Research Brief

Wall Street consensus, price target range, and equity research thesis

Buy41 Analyst Coverage
Consensus Target
$394-3.0% Downside
Current: $406.09
Analyst Range
Low $230High $460
12-Month High/Low Spread
Ratings Mix
22 Buy·16 Hold·3 Sell
Earnings & Valuation
EPS Beat 11.9%
Forward P/E: 17.6x

Executive Summary & Research Take

Wall Street currently rates AMGN buy with a 12-month price target of $394 (-3.0% downside). The sections below cover the bull case, key risks, and latest earnings context for Amgen Inc..

Recent Analyst Actions

AMGN Analyst Upgrades & Price Target Changes

1 of 1 analysts raised targets. Recent price target changes and ratings for AMGN.

Updated Jun 2026
FirmActionRatingPrice Target
Morgan StanleyRaisedEqual-Weight$332$340

Analyst ratings update weekly. Get AMGN's next verdict in your inbox.

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

Analyst Research Summary

Investment Thesis: Bull Case & Risk Factors

A structured look at the bull case, the risks, and the most recent earnings execution for AMGN.

Current setup

AMGN beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.

Bull Case

What keeps the long thesis intact

  • Strong Q4 2025 PerformanceAmgen exceeded revenue and adjusted EPS expectations in Q4 2025, projecting stronger earnings and revenue for 2026.
  • Positive 2026 GuidanceThe company has provided upbeat guidance for 2026, indicating continued growth.
  • Robust Late-Stage PipelineAmgen's late-stage pipeline is expected to drive volume-led growth, particularly with positive Phase 3 data for TEPEZZA.
  • Analyst Consensus RatingAnalysts have a consensus rating of 'Buy' with a median price target of $353.00, implying a potential upside of 4.4%.
  • Long-Term Revenue ProjectionsSome analysts project revenue near $44.4 billion and earnings of about $13.2 billion by 2029, assuming risks are contained.
  • Strong Portfolio and M&A CapacityAmgen's broad portfolio and capacity for mergers and acquisitions are seen as strengths to offset pricing pressures.

Wall Street rates AMGN buy, giving the bull case institutional backing from 41 analysts.

Watch Out For

What can break the setup quickly

  • Upcoming Patent ExpirationsAmgen faces potential headwinds from upcoming patent expirations for key franchises, impacting future revenue.
  • Limited Pipeline VisibilityConcerns about limited pipeline visibility may necessitate continued business development for sustained growth.
  • Intensifying Drug Pricing PressuresThere are growing concerns about global drug pricing efforts that could impact profitability.
  • Stock Valuation ConcernsSome analysts suggest the stock may be overvalued, trading at a higher multiple than historical ranges.
  • Fair Value EstimatesA more cautious view suggests a fair value around $243.49 per share, factoring in pricing reforms and cost inflation.
  • Biosimilar Competition RisksBiosimilar competition and patent expiries are cited as risks that could limit revenue growth.

Watch whether new negative commentary on AMGN points to these structural risks or is simply reacting to short-term price moves.

AMGN Earnings Reaction — What the Last Quarter Showed

Last Quarter

EPS
$6.29 vs $5.62 est.Beat 11.9%
Revenue
$10.1B vs $9.4B est.Beat 6.7%
Consensus & Technical Research Suite
Open AMGN Terminal

AMGN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

AMGN Stock Overview

Stock snapshot, live price chart, key ratios, and company profile.

View Overview

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AMGN — Frequently Asked Questions

Quick answers to the most common questions about buying AMGN stock.

What is the analyst consensus on AMGN?
Verdict

AMGN appears fairly valued near today's $406.09 — the consensus rating is "Buy" with a $394 target (-3.0%). This is informational only — verify the data and consider your own risk tolerance before deciding.

What are recent analyst rating changes for AMGN?
Timing

Timing depends on your horizon, but the data signals are: consensus rating "Buy" with -3.0% upside to the $394 target. In the past 30 days, 1 of 1 covering analysts raised their price targets — a bullish signal.

What is the price target for AMGN stock?
Price Target

AMGN's consensus 12-month price target is $394, set by 41 Wall Street analysts. The bull case high is $460 and the bear case low is $230. From the current price of $406.09, this implies -3.0% upside.

Is AMGN overvalued or undervalued?
Valuation

AMGN appears fairly valued — the $394 consensus target is roughly in line with today's $406.09 (-3.0%). It trades at a forward P/E of 17.6x. Targets range from $230 (bear) to $460 (bull), reflecting different assumptions about growth and margins.

What were AMGN's latest earnings results?
Earnings

AMGN reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $394 target. Consider position sizing rather than going all-in pre-print.

What is the bull case for AMGN?
Coverage

Of 41 analysts covering Amgen Inc. (AMGN): 0 Strong Buy, 22 Buy, 16 Hold, 3 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $394 (range $230–$460). Bullish analysts outnumber bearish by more than 2-to-1.

What are the risks of investing in AMGN?
Risks

3 of the 41 analysts covering AMGN rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Amgen Inc..

Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Consensus ratings and price targets reflect aggregated third-party Wall Street analyst research from public SEC filings. See our Terms of Service and Privacy Policy.